{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:25:15Z","timestamp":1792632315055,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,6,14]],"date-time":"2013-06-14T00:00:00Z","timestamp":1371168000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s00228-013-1525-5","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T07:14:56Z","timestamp":1371107696000},"page":"1777-1784","source":"Crossref","is-referenced-by-count":43,"title":["Influence of chronic hepatitis C infection on cytochrome P450 3a4 activity using midazolam as an in vivo probe substrate"],"prefix":"10.1007","volume":"69","author":[{"given":"P. N.","family":"Morcos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. J.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Blotner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. S.","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. F.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,14]]},"reference":[{"issue":"5","key":"1525_CR1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00228-009-0777-6","volume":"66","author":"AE Jones","year":"2010","unstructured":"Jones AE, Brown KC, Werner RE, Gotzkowsky K, Gaedigk A, Blake M, Hein DW, van der Horst C, Kashuba AD (2010) Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol 66(5):475\u2013485","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1525_CR2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/FTD.0b013e31825a4c3a","volume":"34","author":"I Ince","year":"2012","unstructured":"Ince I, de Wildt SN, Peeters MY, Murry DJ, Tibboel D, Danhof M, Knibbe CA (2012) Critical illness is a major determinant of midazolam clearance in children aged 1\u00a0month to 17\u00a0years. Ther Drug Monit 34(4):381\u2013389","journal-title":"Ther Drug Monit"},{"issue":"2","key":"1525_CR3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1517\/17425255.4.2.137","volume":"4","author":"M Kacevska","year":"2008","unstructured":"Kacevska M, Robertson GR, Clarke SJ, Liddle C (2008) Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol 4(2):137\u2013149","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"1525_CR4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2044.1987.tb03086.x","volume":"42","author":"MP Shelly","year":"1987","unstructured":"Shelly MP, Mendel L, Park GR (1987) Failure of critically ill patients to metabolise midazolam. Anaesthesia 42(6):619\u2013626","journal-title":"Anaesthesia"},{"issue":"3","key":"1525_CR5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1542\/peds.70.3.508","volume":"70","author":"SB Walker","year":"1982","unstructured":"Walker SB, Middelkamp JN (1982) Theophylline toxicity and viral infections. Pediatrics 70(3):508\u2013509","journal-title":"Pediatrics"},{"issue":"6","key":"1525_CR6","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1046\/j.1365-2125.2000.00314.x","volume":"50","author":"PR Mayo","year":"2000","unstructured":"Mayo PR, Skeith K, Russell AS, Jamali F (2000) Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br J Clin Pharmacol 50(6):605\u2013613","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1525_CR7","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/clpt.2011.35","volume":"89","author":"C Schmitt","year":"2011","unstructured":"Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S (2011) Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther 89(5):735\u2013740","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1525_CR8","first-page":"707","volume":"44","author":"Z Abdel-Razzak","year":"1993","unstructured":"Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, Guillouzo A (1993) Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44(4):707\u2013715","journal-title":"Mol Pharmacol"},{"issue":"5","key":"1525_CR9","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.bcp.2004.11.025","volume":"69","author":"X Ding","year":"2005","unstructured":"Ding X, Staudinger JL (2005) Repression of PXR-mediated induction of hepatic CYP3A gene expression by protein kinase C. Biochem Pharmacol 69(5):867\u2013873","journal-title":"Biochem Pharmacol"},{"issue":"4 Pt 1","key":"1525_CR10","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/hep.1840220420","volume":"22","author":"J Muntane-Relat","year":"1995","unstructured":"Muntane-Relat J, Ourlin JC, Domergue J, Maurel P (1995) Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 22(4 Pt 1):1143\u20131153","journal-title":"Hepatology"},{"issue":"3","key":"1525_CR11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/dmd.32.3.359","volume":"32","author":"JA Sunman","year":"2004","unstructured":"Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD (2004) Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos 32(3):359\u2013363","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1525_CR12","first-page":"649","volume":"289","author":"M Tinel","year":"1999","unstructured":"Tinel M, Elkahwaji J, Robin MA, Fardel N, Descatoire V, Haouzi D, Berson A, Pessayre D (1999) Interleukin-2 overexpresses c-myc and down-regulates cytochrome P-450 in rat hepatocytes. J Pharmacol Exp Ther 289(2):649\u2013655","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"1525_CR13","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/0016-5085(95)90648-7","volume":"109","author":"M Tinel","year":"1995","unstructured":"Tinel M, Robin MA, Doostzadeh J, Maratrat M, Ballet F, Fardel N, el Kahwaji J, Beaune P, Daujat M, Labbe G et al (1995) The interleukin-2 receptor down-regulates the expression of cytochrome P450 in cultured rat hepatocytes. Gastroenterology 109(5):1589\u20131599","journal-title":"Gastroenterology"},{"issue":"4","key":"1525_CR14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1517\/17425255.1.4.629","volume":"1","author":"KW Renton","year":"2005","unstructured":"Renton KW (2005) Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol 1(4):629\u2013640","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"1525_CR15","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/COH.0b013e3282f82bf1","volume":"3","author":"L Dickinson","year":"2008","unstructured":"Dickinson L, Khoo S, Back D (2008) Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr Opin HIV AIDS 3(3):296\u2013305","journal-title":"Curr Opin HIV AIDS"},{"issue":"2","key":"1525_CR16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s002280100277","volume":"57","author":"S Grub","year":"2001","unstructured":"Grub S, Bryson H, Goggin T, Ludin E, Jorga K (2001) The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 57(2):115\u2013121","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"1525_CR17","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2165\/00003088-200140120-00002","volume":"40","author":"PF Smith","year":"2001","unstructured":"Smith PF, DiCenzo R, Morse GD (2001) Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 40(12):893\u2013905","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"1525_CR18","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1128\/AAC.49.8.3558-3561.2005","volume":"49","author":"PF Smith","year":"2005","unstructured":"Smith PF, Robbins GK, Shafer RW, Wu H, Yu S, Hirsch MS, Merigan TC, Park JG, Forrest A, Fischl MA, Morse GD (2005) Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors. Antimicrob Agents Chemother 49(8):3558\u20133561","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"1525_CR19","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3851\/IMP1648","volume":"15","author":"A Jetter","year":"2010","unstructured":"Jetter A, Fatkenheuer G, Frank D, Klaassen T, Seeringer A, Doroshyenko O, Kirchheiner J, Hein W, Schomig E, Fuhr U, Wyen C (2010) Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients? Antivir Ther 15(7):975\u2013983","journal-title":"Antivir Ther"},{"issue":"8074","key":"1525_CR20","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S0140-6736(78)90305-7","volume":"1","author":"KC Chang","year":"1978","unstructured":"Chang KC, Bell TD, Lauer BA, Chai H (1978) Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1(8074):1132\u20131133","journal-title":"Lancet"},{"issue":"5","key":"1525_CR21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/gut.17.5.341","volume":"17","author":"DA Burnett","year":"1976","unstructured":"Burnett DA, Barak AJ, Tuma DJ, Sorrell MF (1976) Altered elimination of antipyrine in patients with acute viral hepatitis. Gut 17(5):341\u2013344","journal-title":"Gut"},{"issue":"4","key":"1525_CR22","doi-asserted-by":"crossref","first-page":"1216a","DOI":"10.1002\/hep.23850","volume":"52","author":"DM Brainard","year":"2010","unstructured":"Brainard DM, Petry A, Anderson MS, Mitselos A, Laethem T, Heirman I, Caro L, Stone JA, Sun P, Panorchan P, Van Bortel LM, Iwamoto M, Wagner JA (2010) Safety, tolerability, and pharmacokinetics alter single and multiple doses of Mk-5172, a novel Hcv Ns3\/4a protease inhibitor with potent activity against known resistance mutants, in healthy subjects. Hepatology 52(4):1216a\u20131217a","journal-title":"Hepatology"},{"issue":"9751","key":"1525_CR23","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","volume":"376","author":"EJ Gane","year":"2010","unstructured":"Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF (2010) Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376(9751):1467\u20131475","journal-title":"Lancet"},{"issue":"4","key":"1525_CR24","first-page":"717a","volume":"52","author":"R Goldwater","year":"2010","unstructured":"Goldwater R, DeMicco MP, Zong JA, Chittick GE, Yuen GJ, West S, Kagel J, Bae A, Mo HM, Oldach D, Delaney WE, Findlay JW (2010) Safety, Pharmacokinetics, and Antiviral Activity of Single Oral Doses of the Hcv Ns3 Protease Inhibitor Gs 9256. Hepatology 52(4):717a\u2013718a","journal-title":"Hepatology"},{"issue":"3","key":"1525_CR25","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1053\/j.gastro.2009.10.033","volume":"138","author":"HW Reesink","year":"2010","unstructured":"Reesink HW, Fanning GC, Farha KA, Weegink C, Van Vliet A, Van 't Klooster G, Lenz O, Aharchi F, Marien K, Van Remoortere P, de Kock H, Broeckaert F, Meyvisch P, Van Beirendonck E, Simmen K, Verloes R (2010) Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 138(3):913\u2013921","journal-title":"Gastroenterology"},{"issue":"6","key":"1525_CR26","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1399-0012.2004.00256.x","volume":"18","author":"L Wolffenbuttel","year":"2004","unstructured":"Wolffenbuttel L, Poli DD, Manfro RC, Goncalves LF (2004) Cyclosporine pharmacokinetics in anti-HCV\u2009+\u2009patients. Clin Transplant 18(6):654\u2013660","journal-title":"Clin Transplant"},{"issue":"2","key":"1525_CR27","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/AAC.49.2.643-649.2005","volume":"49","author":"M Regazzi","year":"2005","unstructured":"Regazzi M, Maserati R, Villani P, Cusato M, Zucchi P, Briganti E, Roda R, Sacchelli L, Gatti F, Delle Foglie P, Nardini G, Fabris P, Mori F, Castelli P, Testa L (2005) Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects. Antimicrob Agents Chemother 49(2):643\u2013649","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1525_CR28","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/jac\/dkq320","volume":"65","author":"S Dominguez","year":"2010","unstructured":"Dominguez S, Ghosn J, Peytavin G, Guiguet M, Tubiana R, Valantin MA, Murphy R, Bricaire F, Benhamou Y, Katlama C (2010) Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study. J Antimicrob Chemother 65(11):2445\u20132449","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1525_CR29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","volume":"345","author":"GM Lauer","year":"2001","unstructured":"Lauer GM, Walker BD (2001) Hepatitis C virus infection. N Engl J Med 345(1):41\u201352","journal-title":"N Engl J Med"},{"issue":"4","key":"1525_CR30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7326\/0003-4819-132-4-200002150-00008","volume":"132","author":"TJ Liang","year":"2000","unstructured":"Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH (2000) Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132(4):296\u2013305","journal-title":"Ann Intern Med"},{"issue":"5","key":"1525_CR31","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/jac\/dkr595","volume":"67","author":"M Guzman-Fulgencio","year":"2012","unstructured":"Guzman-Fulgencio M, Jimenez JL, Berenguer J, Fernandez-Rodriguez A, Lopez JC, Cosin J, Miralles P, Micheloud D, Munoz-Fernandez MA, Resino S (2012) Plasma IL-6 and IL-9 predict the failure of interferon-alpha plus ribavirin therapy in HIV\/HCV-coinfected patients. J Antimicrob Chemother 67(5):1238\u20131245","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"1525_CR32","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3851\/IMP1864","volume":"16","author":"M Ueyama","year":"2011","unstructured":"Ueyama M, Nakagawa M, Sakamoto N, Onozuka I, Funaoka Y, Watanabe T, Nitta S, Kiyohashi K, Kitazume A, Murakawa M, Nishimura-Sakurai Y, Sekine-Osajima Y, Itsui Y, Azuma S, Kakinuma S, Watanabe M (2011) Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-alpha2b plus ribavirin. Antivir Ther 16(7):1081\u20131091","journal-title":"Antivir Ther"},{"issue":"9","key":"1525_CR33","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1124\/dmd.107.015511","volume":"35","author":"AE Aitken","year":"2007","unstructured":"Aitken AE, Morgan ET (2007) Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 35(9):1687\u20131693","journal-title":"Drug Metab Dispos"},{"issue":"13","key":"1525_CR34","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1096\/fj.02-0195fje","volume":"16","author":"R Jover","year":"2002","unstructured":"Jover R, Bort R, Gomez-Lechon MJ, Castell JV (2002) Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J 16(13):1799\u20131801","journal-title":"FASEB J"},{"issue":"4","key":"1525_CR35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00008571-199408000-00001","volume":"4","author":"PB Watkins","year":"1994","unstructured":"Watkins PB (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4(4):171\u2013184","journal-title":"Pharmacogenetics"},{"issue":"5","key":"1525_CR36","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jhep.2011.01.046","volume":"55","author":"EJ Gane","year":"2011","unstructured":"Gane EJ, Rouzier R, Stedman C, Wiercinska-Drapalo A, Horban A, Chang L, Zhang Y, Sampeur P, Najera I, Smith P, Shulman NS, Tran JQ (2011) Antiviral activity, safety, and pharmacokinetics of danoprevir\/ritonavir plus PEG-IFN alpha-2a\/RBV in hepatitis C patients. J Hepatol 55(5):972\u2013979","journal-title":"J Hepatol"},{"issue":"6","key":"1525_CR37","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/0091270007312153","volume":"48","author":"SM Huang","year":"2008","unstructured":"Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei XX, Yasuda S, Zheng JH, Zhao H, Lesko LJ (2008) New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48(6):662\u2013670","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"1525_CR38","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1177\/0091270010387792","volume":"51","author":"TC Marbury","year":"2011","unstructured":"Marbury TC, Ngo PL, Shadle CR, Jin B, Panebianco D, Caro L, Valentine J, Murphy G (2011) Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150\u00a0mg fosaprepitant in healthy adult subjects. J Clin Pharmacol 51(12):1712\u20131720","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"1525_CR39","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1177\/0091270003259216","volume":"43","author":"YW Lam","year":"2003","unstructured":"Lam YW, Alfaro CL, Ereshefsky L, Miller M (2003) Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol 43(11):1274\u20131282","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1525_CR40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0041-1345(01)02678-1","volume":"34","author":"A Latorre","year":"2002","unstructured":"Latorre A, Morales E, Gonzalez E, Herrero JC, Ortiz M, Sierra P, Dominguez-Gil B, Torres A, Munoz MA, Andres A, Manzanares C, Morales JM (2002) Clinical management of renal transplant patients with hepatitis C virus infection treated with cyclosporine or tacrolimus. Transplant Proc 34(1):63\u201364","journal-title":"Transplant Proc"},{"key":"1525_CR41","unstructured":"Petry AS, Fraser IP, Van Dyck K, Nachbar RB, De Lepeleire I, Robberechts M, Han L, Palcza J, Moiseev VS, Kobalava ZD, Uhle M, Wagner F, O'Mara E, Wagner JA (2011) Safety and antiviral activity of MK-5172, a next generation HCV NS3\/4a protease inhibitor with a broad HCV genotypic activity spectrum and potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Hepatology 52(4)"},{"issue":"3","key":"1525_CR42","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1124\/dmd.108.023630","volume":"37","author":"ML Vee","year":"2009","unstructured":"Vee ML, Lecureur V, Stieger B, Fardel O (2009) Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab Dispos 37(3):685\u2013693","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1525_CR43","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.virol.2006.02.023","volume":"349","author":"A Basu","year":"2006","unstructured":"Basu A, Meyer K, Lai KK, Saito K, Di Bisceglie AM, Grosso LE, Ray RB, Ray R (2006) Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. Virology 349(2):347\u2013358","journal-title":"Virology"},{"issue":"5","key":"1525_CR44","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/hep.21853","volume":"46","author":"JJ Feld","year":"2007","unstructured":"Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, Schweigler LM, Theodore D, Zacks SL, Liang TJ, Fried MW (2007) Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 46(5):1548\u20131563","journal-title":"Hepatology"},{"issue":"7","key":"1525_CR45","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1128\/AAC.00131-11","volume":"55","author":"CJ Schaefer","year":"2011","unstructured":"Schaefer CJ, Kossen K, Lim SR, Lin JH, Pan L, Bradford W, Smith PF, Seiwert SD (2011) Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother 55(7):3125\u20133132","journal-title":"Antimicrob Agents Chemother"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1525-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-013-1525-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1525-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:47:29Z","timestamp":1645750049000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-013-1525-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,14]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["1525"],"URL":"https:\/\/doi.org\/10.1007\/s00228-013-1525-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,14]]}}}